News & Updates

Nadofaragene firadenovec promotes bladder preservation in BCG-unresponsive NMIBC

05 Jul 2024 by

Nadofaragene firadenovec-vncg helps preserve the bladder in patients with bacillus Calmette-Guérin (BCG)-unresponsive nonmuscle-invasive bladder cancer (NMIBC) at 5 years, with an acceptable safety profile, as shown in a phase III trial.

Nadofaragene firadenovec promotes bladder preservation in BCG-unresponsive NMIBC

05 Jul 2024

ctDNA EGFRm helps pinpoint who benefits from 1L osimertinib-chemo combo

05 Jul 2024 by

Detectable EGFRm in plasma ctDNA prior to treatment may define a subgroup of patients with advanced EGFRm NSCLC who would derive the most benefit from the addition of chemo to 1L osimertinib, according to an exploratory analysis of FLAURA2 presented at AACR 2024

ctDNA EGFRm helps pinpoint who benefits from 1L osimertinib-chemo combo

05 Jul 2024

Bladder cancer survivors who do not smoke enjoy better life quality

04 Jul 2024

Among patients with bladder cancer (BC), those who do not smoke appear to have better longitudinal health-related quality of life (HRQoL) measures, particularly in the domains of physical function, emotional function, and fatigue, according to a recent study.

Bladder cancer survivors who do not smoke enjoy better life quality

04 Jul 2024

Follow-up testing in cervical cancer screening remains low in SG

03 Jul 2024 by

A recent study has found an “unacceptably low” compliance of follow-up following abnormal human papillomavirus (HPV) tests among women in Singapore.

Follow-up testing in cervical cancer screening remains low in SG

03 Jul 2024

EUS-guided gastroenterostomy efficient in both benign, malignant diseases

03 Jul 2024

The novel endoscopic ultrasound (EUS)-guided gastroenterostomy (GE) is effective in patients with either a malignant or a benign disease, reports a study. In addition, adverse events are similar in both groups.

EUS-guided gastroenterostomy efficient in both benign, malignant diseases

03 Jul 2024

Neoadjuvant avelumab plus cisplatin-based chemo confers high OS, EFS rates in MIUC

03 Jul 2024 by

The combination of avelumab and cisplatin-based chemotherapy as neoadjuvant therapy for MIUC yields high OS and EFS rates at both 1 and 3 years, according to the survival data from the dual-cohort, phase II AURA trial presented at ASCO 2024

Neoadjuvant avelumab plus cisplatin-based chemo confers high OS, EFS rates in MIUC

03 Jul 2024

Vaginal estrogen therapy safe for some breast cancer patients, but may pose risk for others

02 Jul 2024 by

Vaginal estrogen therapy may be safely used to treat genitourinary symptoms in early-stage breast cancer patients with HR-negative tumours and in those concurrently treated with tamoxifen, according to the results of a target trial emulation. However, its use may be detrimental to disease-free survival (DFS) outcomes in patients receiving aromatase inhibitors.

Vaginal estrogen therapy safe for some breast cancer patients, but may pose risk for others

02 Jul 2024

Novel personalized cancer vaccine may delay relapse in HNSCC

02 Jul 2024 by

TG4050, a novel viral-based personalized cancer vaccine, showed promise in a phase I trial presented during a late-breaking poster presentation at AACR 2024. The investigational vaccine induced polyepitopic immune responses against private neoantigens in resected HPV-negative head and neck squamous cell cancer (HNSCC).

Novel personalized cancer vaccine may delay relapse in HNSCC

02 Jul 2024

Exercise boosts sexual health in metastatic breast cancer patients

01 Jul 2024 by

Working out can improve sexual function as well as reduce endocrine sexual symptoms in patients with metastatic breast cancer (mBC), according to data from the PREFERABLE-EFFECT trial.

Exercise boosts sexual health in metastatic breast cancer patients

01 Jul 2024

Wasting disorders overlooked in older adults with cancer

01 Jul 2024

Many wasting disorders remain under-recognized and undertreated among older adults with cancer, and there exists a need to properly identify and manage these conditions, suggests a study.

Wasting disorders overlooked in older adults with cancer

01 Jul 2024

News & Updates

Filter by Specialty:

Specialty:

Nadofaragene firadenovec promotes bladder preservation in BCG-unresponsive NMIBC

Nadofaragene firadenovec promotes bladder preservation in BCG-unresponsive NMIBC

ctDNA EGFRm helps pinpoint who benefits from 1L osimertinib-chemo combo

ctDNA EGFRm helps pinpoint who benefits from 1L osimertinib-chemo combo

Bladder cancer survivors who do not smoke enjoy better life quality

Bladder cancer survivors who do not smoke enjoy better life quality

Follow-up testing in cervical cancer screening remains low in SG

Follow-up testing in cervical cancer screening remains low in SG

EUS-guided gastroenterostomy efficient in both benign, malignant diseases

EUS-guided gastroenterostomy efficient in both benign, malignant diseases

Neoadjuvant avelumab plus cisplatin-based chemo confers high OS, EFS rates in MIUC

Neoadjuvant avelumab plus cisplatin-based chemo confers high OS, EFS rates in MIUC

Vaginal estrogen therapy safe for some breast cancer patients, but may pose risk for others

Vaginal estrogen therapy safe for some breast cancer patients, but may pose risk for others

Novel personalized cancer vaccine may delay relapse in HNSCC

Novel personalized cancer vaccine may delay relapse in HNSCC

Exercise boosts sexual health in metastatic breast cancer patients

Exercise boosts sexual health in metastatic breast cancer patients

Wasting disorders overlooked in older adults with cancer

Wasting disorders overlooked in older adults with cancer